ICPT - Intercept Pharmaceuticals, Inc. Stock Price and Quote

ICPT [NASD]

Index	-	P/E	-	EPS (ttm)	-6.07	Insider Own	0.60%	Shs Outstand	41.42M	Perf Week	8.97%
Market Cap	793.13M	Forward P/E	-	EPS next Y	-2.72	Insider Trans	0.00%	Shs Float	39.98M	Perf Month	44.07%
Income	-194.10M	PEG	-	EPS next Q	-0.17	Inst Own	80.60%	Short Float / Ratio	8.82% / 4.77	Perf Quarter	29.73%
Sales	300.90M	P/S	2.64	EPS this Y	65.60%	Inst Trans	15.42%	Short Interest	3.53M	Perf Half Y	19.06%
Book/sh	3.14	P/B	6.06	EPS next Y	-141.50%	ROA	39.50%	Target Price	22.50	Perf Year	31.65%
Cash/sh	11.77	P/C	1.62	EPS next 5Y	-8.89%	ROE	-100.90%	52W Range	10.81 - 21.25	Perf YTD	58.04%
Dividend	-	P/FCF	-	EPS past 5Y	29.70%	ROI	-11.00%	52W High	-8.00%	Beta	1.28
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	70.90%	Gross Margin	99.30%	52W Low	80.85%	ATR	0.86
Employees	437	Current Ratio	2.50	Sales Q/Q	16.50%	Oper. Margin	-54.10%	RSI (14)	72.23	Volatility	3.73% 5.93%
Optionable	Yes	Debt/Eq	3.09	EPS Q/Q	-468.60%	Profit Margin	68.60%	Rel Volume	0.57	Prev Close	19.02
Shortable	Yes	LT Debt/Eq	2.07	Earnings	Nov 01 BMO	Payout	0.00%	Avg Volume	738.66K	Price	19.55
Recom	2.70	SMA20	16.31%	SMA50	30.39%	SMA200	26.81%	Volume	69,944	Change	2.79%

Jan-11-22

Upgrade

B. Riley Securities

Neutral → Buy

$25 → $30

Aug-20-21

Downgrade

Goldman

Neutral → Sell

$17 → $10

May-25-21

Downgrade

B. Riley Securities

Buy → Neutral

$18

Mar-12-21

Upgrade

H.C. Wainwright

Sell → Neutral

$21

Feb-23-21

Downgrade

H.C. Wainwright

Neutral → Sell

$25

Jan-15-21

Downgrade

BofA Securities

Neutral → Underperform

$40 → $27

Dec-21-20

Downgrade

Jefferies

Buy → Hold

$30

Nov-10-20

Upgrade

Robert W. Baird

Neutral → Outperform

$52

Nov-10-20

Upgrade

Raymond James

Mkt Perform → Outperform

$60

Jul-31-20

Initiated

Piper Sandler

Overweight

$82

Show Previous Ratings

Jan-25-23 04:06PM	Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years Investor's Business Daily +14.36%
Jan-20-23 09:55AM	Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect? Zacks
09:53AM	Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA Zacks
Jan-19-23 08:00AM	FDA Accepts Intercepts New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH GlobeNewswire
Jan-13-23 11:41AM	Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why Zacks
08:00AM	Loading…
Jan-05-23 08:00AM	Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023 GlobeNewswire +5.60%
Jan-04-23 09:00AM	Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023 GlobeNewswire
Dec-23-22 07:50AM	Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH GlobeNewswire -12.18%
Dec-20-22 11:15AM	Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study Zacks +5.11%
Dec-19-22 04:08PM	Madrigal Pharmaceuticals Stock More Than Doubles on NASH Breakthrough Barrons.com -23.47%
01:33PM	Madrigal Pharmaceuticals Hits the NASH Jackpot. Its Stock Is Up 240%. Barrons.com
Dec-08-22 06:00PM	New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease GlobeNewswire
Dec-05-22 08:29AM	Analysts Expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) To Breakeven Soon Simply Wall St.
Dec-01-22 11:31AM	Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report? Zacks
Nov-22-22 08:00AM	Intercept Pharmaceuticals to Participate in Piper Sandlers 34th Annual Healthcare Conference on December 1, 2022 GlobeNewswire
07:37AM	Loading…
Nov-08-22 07:37AM	Intercept Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag Simply Wall St.
Nov-07-22 06:55PM	Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis GlobeNewswire
08:00AM	Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 GlobeNewswire
Nov-06-22 08:00AM	Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 GlobeNewswire
Nov-02-22 11:38AM	Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised Zacks
Nov-01-22 12:09PM	Why Intercept Pharmaceuticals Stock Is Soaring Today Motley Fool +13.41%
08:15AM	Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Oct-31-22 04:05PM	Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022 GlobeNewswire
Oct-30-22 10:40AM	Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested three years ago Simply Wall St.
Oct-26-22 10:01AM	Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline Zacks
Oct-25-22 08:00AM	Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022 GlobeNewswire
Oct-12-22 08:40AM	Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options Zacks
08:00AM	Intercept Pharmaceuticals to Participate in H.C. Wainwrights 6th Annual NASH Investor Conference on October 17, 2022 GlobeNewswire
Oct-06-22 10:28AM	Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More Zacks
09:24AM	Loading…
Oct-02-22 09:24AM	Institutional owners may take dramatic actions as Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) recent 8.5% drop adds to one-year losses Simply Wall St.
Sep-30-22 04:08PM	Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients Investor's Business Daily -14.99%
09:44AM	Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday Motley Fool
07:55AM	Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint GlobeNewswire
Sep-26-22 10:46AM	Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why Zacks
Sep-21-22 11:33AM	Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning Benzinga -16.85%
07:30AM	Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning GlobeNewswire
Sep-20-22 12:45PM	Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology GlobeNewswire
09:03AM	A Chronic Disease Still Waiting for a Drug The Wall Street Journal
Sep-14-22 01:35PM	Akero Therapeutics (AKRO) Up on Positive Data from NASH Study Zacks
Sep-08-22 11:30AM	Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report? Zacks
Sep-07-22 08:00AM	Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences GlobeNewswire
Sep-02-22 11:31AM	Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report? Zacks
Aug-29-22 10:49AM	Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options Zacks
08:00AM	Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022 GlobeNewswire
Aug-19-22 07:30AM	Intercept Pharmaceuticals Announces Repurchase of Convertible Notes GlobeNewswire -9.95%
Aug-18-22 10:20AM	Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva Zacks +5.18%
08:00AM	Intercept Pharmaceuticals to Participate in B. Rileys PBC Symposium on August 24, 2022 GlobeNewswire
Aug-17-22 10:16AM	Intercept Settles Ocaliva Litigation With Reddy's Lab Benzinga
Aug-05-22 04:31AM	Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised) Zacks
04:27AM	Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised) Zacks
Aug-04-22 09:18AM	Intercept (ICPT) Earnings and Sales Miss Estimates in Q2 Zacks +13.08%
Aug-03-22 01:05PM	Intercept Shares Jump After Reissuing Annual Guidance Benzinga +12.98%
08:30AM	Edited Transcript of ICPT.OQ earnings conference call or presentation 3-Aug-22 12:30pm GMT Thomson Reuters StreetEvents
08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM	Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Aug-01-22 10:01AM	Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-27-22 08:00AM	Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 GlobeNewswire
Jul-19-22 09:26AM	10 Most Shorted Stocks to Watch in July Insider Monkey
Jul-18-22 06:00PM	7 Biotech Stocks to Buy for Q3 InvestorPlace
Jul-08-22 12:53PM	Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path Benzinga
11:12AM	Intercept (ICPT) Reports Positive Data From NASH Study on OCA Zacks
11:12AM	The NASH Drug Dream Isnt Dead Yet. Intercept is Asking FDA for Approval Again. Barrons.com
Jul-07-22 11:23AM	Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt Zacks
08:06AM	UPDATE 2-Intercept to go back to FDA with its NASH treatment application Reuters
07:30AM	Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) GlobeNewswire
Jul-01-22 04:01PM	Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. GlobeNewswire
Jun-24-22 08:08AM	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic? Simply Wall St.
Jun-21-22 07:30AM	Intercept Announces PBC Data Presentations at The International Liver Congress 2022 GlobeNewswire +5.05%
Jun-07-22 10:06AM	Intercept (ICPT) Announces Delay in Meeting With the FDA Zacks
Jun-06-22 02:45PM	Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again Benzinga -10.74%
06:30AM	Intercept Provides Update on NASH Regulatory Timeline GlobeNewswire
Jun-03-22 07:30AM	Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC GlobeNewswire -7.20%
May-13-22 08:42AM	The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical Zacks
May-12-22 09:11AM	Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News Zacks
May-11-22 08:00AM	Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis GlobeNewswire -8.79%
May-10-22 06:16AM	Party Time: Brokers Just Made Major Increases To Their Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Earnings Forecasts Simply Wall St.
May-09-22 02:15PM	Analysts Expect Clarity Imminent On Intercept's NASH Story Benzinga -6.54%
May-06-22 08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
May-05-22 04:21PM	Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug Investor's Business Daily +21.00%
08:25AM	Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:17AM	Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments GlobeNewswire
May-04-22 06:15PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates Zacks
May-02-22 08:00AM	Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022 GlobeNewswire
Apr-27-22 05:06AM	3 Moonshot Stocks With Upside of Up to 709%, According to Wall Street Motley Fool
Apr-22-22 11:36AM	Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead? Zacks
Apr-07-22 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates Zacks
Apr-01-22 11:30AM	Intercept (ICPT) Up 15.4% Since Last Earnings Report: Can It Continue? Zacks
05:13AM	Top Biotech Stocks for Q2 2022 Investopedia
Mar-03-22 11:03AM	Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus Zacks
Mar-02-22 08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates Zacks -9.60%
07:02AM	2 Biotech Stocks That Could Make You Richer Motley Fool
07:00AM	Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update GlobeNewswire
Feb-23-22 08:49AM	Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022 GlobeNewswire -5.11%
Feb-17-22 03:03PM	Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-15-22 11:02AM	Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested five years ago Simply Wall St. +7.27%
Feb-10-22 03:36PM	3 Biotech Stocks That Are too Cheap to Ignore Motley Fool
Jan-29-22 05:51AM	4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street Motley Fool
Jan-18-22 01:38PM	HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ... GuruFocus.com -6.76%

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience